TB treatment drugs will become more accessible due to cheaper prices following Johnson & Johnson’s decision not to use its patents.
TB Treatment Drugs Will Increase Availability Due to Johnson & Johnson’s Decision to Stop Enforcing Its Patents
TB treatment drugs called Bedaquiline are expected to increase accessibility and availability in the market after Johnson & Johnson decided to stop enforcing its patents to the TB treatment drugs, which would result in cheaper prices offered to millions of Americans.
According to a report published in Mother Jones, TB treatment drugs helped many young children and other vulnerable groups from suffering from tuberculosis as vaccines do not guarantee full protection against the virus; however, TB treatment drugs have always been inaccessible to some residents due to their high prices.
Following the increasing prices of the TB treatment drugs, Johnson & Johnson decided to stop enforcing their patents in TB treatment drugs, which would eventually reduce their prices and increase their availability across the country.
TB Treatment Drugs Available in Lower Prices Following Johnson & Johnson’s Decision to Stop Enforcing Patents
With Johnson & Johnson’s decision, organizations and other advocates celebrated following the possibility of TB treatment drugs being available at lower prices after patents only increased TB treatment drugs’ prices.
The lowering prices of TB treatment drugs could help millions of people suffering from tuberculosis, who have been calling for more affordable medication, ABC News reported.
READ ALSO: Novel Synthetic Opioids Could Be 1,000 Times More Powerful Than Morphine, Deadlier Than Fentanyl
Leave a Reply